Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee. Breazzano is now with The Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland.
School of Medicine, Vanderbilt University, Nashville, Tennessee.
Retin Cases Brief Rep. 2022 Nov 1;16(6):775-778. doi: 10.1097/ICB.0000000000001081.
Melanoma-associated retinopathy responds poorly to currently-available therapies, with continued chronic decline in visual function being the norm, despite treatment. The purpose of this report is to describe the excellent response of a patient with melanoma-associated retinopathy to a triple therapy regimen of rituximab, intravenous immunoglobulin, and intravitreal corticosteroids.
Single interventional case report describing management of melanoma-associated retinopathy and the patient's response to this treatment. Retinal function was monitored by serial visual acuity, fundus exams, Goldmann visual fields, and electroretinography.
A 65-year old man presented with new onset photopsia, decrease visual acuity and nyctalopia in both eyes in the setting of recently-diagnosed Stage IIIB melanoma, initially treated with wide local excision and adjuvant interferon. He was diagnosed with melanoma-associated retinopathy that initially worsened during his course of interferon for treatment of the melanoma. We initiated triple therapy with rituximab, intravenous immunoglobulin, and intravitreal corticosteroids, and this resulted in full return of electroretinography function and resumption of 20/20 visual acuity in both eyes.
This is the first reported case of the utility of triple therapy with rituximab, intravenous immunoglobulin, and intravitreal steroids for successful management of melanoma-associated retinopathy as demonstrated by improvement in acuity, symptoms, visual fields, and electroretinography.
黑色素瘤相关性视网膜病变对目前可用的治疗方法反应不佳，尽管进行了治疗，但视觉功能仍持续慢性下降。本报告的目的是描述一名黑色素瘤相关性视网膜病变患者对利妥昔单抗、静脉注射免疫球蛋白和玻璃体内皮质类固醇三联疗法的极佳反应。
单例介入性病例报告，描述了黑色素瘤相关性视网膜病变的治疗方法以及该患者对该治疗的反应。通过连续视力、眼底检查、Goldmann 视野和视网膜电图监测视网膜功能。
一名 65 岁男性因新近诊断的 IIIB 期黑色素瘤，最初接受广泛局部切除和辅助干扰素治疗，出现双眼新发性光幻视、视力下降和夜盲。他被诊断为黑色素瘤相关性视网膜病变，在接受干扰素治疗黑色素瘤的过程中病情最初恶化。我们开始使用利妥昔单抗、静脉注射免疫球蛋白和玻璃体内皮质类固醇进行三联治疗，这导致视网膜电图功能完全恢复，双眼视力恢复到 20/20。
这是首例报道的利妥昔单抗、静脉注射免疫球蛋白和玻璃体内皮质类固醇三联治疗成功管理黑色素瘤相关性视网膜病变的病例，其表现为视力、症状、视野和视网膜电图的改善。
